Protocol Ledger

NCT04849351 · Phase II · COMPLETED

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Interventional Phase II clinical trial protocol NCT04849351 sponsored by Hutchison Medipharma Limited in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-15 Enrollment: 178 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04849351
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)178 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04849351
Protocol FieldVerified Registry Value
NCT IdentifierNCT04849351
Consolidated Lead SponsorHutchison Medipharma Limited
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment178 participants (ACTUAL)
Registered Start Date2021-04-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI